Paper Details

  1. Home
  2. Paper Details

Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline.

Author: AlimenaGiuliana, ArboscelloEleonora, BellodiAndrea, BergamaschiMicaela, BrecciaMassimo, ColafigliGioia, MassaroFulvio, MolicaMatteo, QuattrocchiLuisa, SarocchiMatteo, SpallarossaPaolo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This paper focuses on the optimal procedures to perform at diagnosis in order to identify patients at risk of possible metabolic and cardiovascular adverse events caused by nilotinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia patients. It also explores the correct monitoring procedures to prevent and manage these adverse events.
Paper Details　
Original Abstract of the Article :
Nilotinib was approved for chronic myeloid leukemia patients in chronic phase or accelerated phase after resistance to imatinib or as frontline treatment. The drug, as other tyrosine kinase inhibitor has a specific safety profile with possible occurring metabolic side effects, such as increased glyc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.critrevonc.2016.10.002

データ提供：米国国立医学図書館（NLM）

Nilotinib for Chronic Myeloid Leukemia: Navigating Cardiovascular Considerations

Chronic myeloid leukemia (CML) is a serious blood cancer, and tyrosine kinase inhibitors (TKIs), such as nilotinib, have become crucial tools in its management. However, like any medication, TKIs can have side effects. This study examines the potential cardiovascular risks associated with nilotinib treatment, focusing on the importance of early identification and preventive measures.

A Careful Approach to CML Treatment: Managing Cardiovascular Risks

The study emphasizes the need for a comprehensive approach to managing cardiovascular risks in CML patients treated with nilotinib. The researchers suggest that thorough baseline evaluations and ongoing monitoring are essential to identify patients at risk and implement preventative strategies.

Staying Safe on the Path to Recovery: Cardiovascular Monitoring in CML Treatment

This research provides valuable guidance for healthcare professionals treating CML patients with nilotinib. It highlights the importance of early risk assessment, regular monitoring, and prompt intervention to minimize the potential for cardiovascular complications.

Dr.Camel's Conclusion

The journey of CML treatment, like a long and winding desert road, requires careful navigation. This study reminds us that while TKIs offer hope for patients, their use necessitates vigilant monitoring and proactive management of potential cardiovascular risks.

Date :
  1. Date Completed 2019-03-27
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

27823647

DOI: Digital Object Identifier

10.1016/j.critrevonc.2016.10.002

Related Literature

Article Analysis
・Effects of nilotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.